Dong-A ST (KOSPI 170900) Stock Outlook 2026: Stelara Biosimilar Royalties Meet Legacy Pharma

Start by asking what you are actually buying

The first question a US investor should ask about Dong-A ST is blunt: am I buying a cheap legacy pharma, or a growth story re-rated by biosimilar royalties? These are two different theses, and blending them is how people end up disappointed.

My read is this. The body of Dong-A ST is a slow-growing traditional prescription-drug business squeezed by Korea’s relentless drug-price policy. Bolted on top is a catalyst: the global out-licensing of IMULDOSA, a Stelara (ustekinumab) biosimilar with US and EU approvals. The catalyst is what moves the stock; the legacy body is what supports the floor. Investors who hold both ideas in their head at once get hurt less here.

The mechanics of IMULDOSA are the whole game. Dong-A ST does not sell this biosimilar itself overseas. It licenses commercialization to global partners — Intas and its Accord arm across Europe and emerging markets, plus a separate route into the US. In other words, Dong-A ST skips the enormous cost and risk of building a global sales organization and instead participates through approval, supply, and royalties. For a mid-cap pharma, that is a rational trade.

The cost of that trade is the upside. An out-licensing model shares the top end with partners. How much IMULDOSA sells in the US and Europe is decided not by Dong-A ST but by the partner’s commercial muscle, its pricing strategy, and the share fight inside an already crowded ustekinumab biosimilar market. Lower risk in exchange for ceded control.

👉 For a sense of how Korean healthcare names cycle after a demand shock, compare with the SD Biosensor (137310) stock outlook, a diagnostics company normalizing after its COVID windfall.

---

What kind of opportunity is IMULDOSA?

Stelara was one of Johnson & Johnson’s largest autoimmune franchises — ustekinumab, prescribed for psoriasis, Crohn’s disease and ulcerative colitis. When its patents expired, biosimilar developers piled in, and the market is worth billions. IMULDOSA is Dong-A ST’s entry in that race.

Break the appeal into layers.

First, it is an approval asset. Biosimilars have to clear high clinical and regulatory bars. That IMULDOSA holds both FDA and EMA approval is itself hard to replicate — a latecomer would need years and serious money to reach the same starting line.

Second, it is partner channel access. Intas/Accord is a large global generics and biosimilar player with real distribution across Europe and emerging markets. Dong-A ST rents that network instantly instead of spending a decade building one, and the US route opens the world’s biggest autoimmune market.

Third, it is a supply-plus-royalty cash structure. Out-licensing deals typically bundle milestone payments, finished-product or drug-substance supply revenue, and sales-linked royalties. As partner sales grow, royalties accrue — high-margin cash that costs Dong-A ST almost nothing in selling expense.

IMULDOSA value driver	What Dong-A ST gets	Who controls it
US and EU approvals	A hard-to-replicate entry asset	Already secured
Partner distribution	Instant global channel	Partner-controlled
Supply revenue	Product supply payments	Partly controlled
Sales royalties	Sales-linked cash flow	Depends on partner selling

That last row is the crux. The size of the upside sits in the partner’s hands, not Dong-A ST’s. The gap between “approved but negligible share” and “partner pushes it to meaningful share” is the single biggest variable in valuing this stock.

---

What role do Growtropin and the legacy body play?

If IMULDOSA is the story, Growtropin and the traditional prescription book are the valuation floor.

Growtropin is Dong-A ST’s growth hormone, prescribed for pediatric short stature and related conditions — a long-standing cash cow. Growth hormone is a category with sticky brand trust and prescribing inertia, so once you hold share, revenue stays reasonably stable. Management flags adult indications and exports as incremental room.

The ethical (ETC) body is a prescription portfolio across gastrointestinal, anti-infective, cardiovascular and other categories. It throws off steady cash but is structurally slow-growing at home, and the reason is policy. Korea’s persistent drug-price cuts keep pressing prices on both off-patent originals and generics. Revenue locked inside the domestic market is more about defense than growth.

This is exactly where the thesis sharpens. A slow, domestically trapped body holds the floor; biosimilars and licensing going abroad open the ceiling. Look only at the body and it is a dull stock. Add the overseas catalyst and it becomes a name with real re-rating potential.

---

What is the real weakness of the out-licensing model?

Out-licensing is a sensible strategy for a smaller pharma, but it has a structural weakness investors must internalize.

Partner dependence. IMULDOSA’s overseas revenue rides on how well the partner sells. If the partner prioritizes its own products, or goes soft in a given market, Dong-A ST has limited levers to intervene. That is the price of ceding control.

Profit split. Direct sales book 100% of revenue; out-licensing books only the royalty slice. In a structure where the partner keeps most of the margin, even a well-selling IMULDOSA can return a smaller absolute dollar figure to Dong-A ST than direct sales would.

Biosimilar price collapse. The Stelara biosimilar market is already crowded. Biosimilars see prices fall fast as competitors multiply after launch. Early royalties may look good, but two or three years on, intensifying price competition can flatten or shrink the royalty dollars.

Opaque contract terms. Exact royalty rates and milestone structures are usually undisclosed. Investors have to back into estimates from the partner’s public results and Dong-A ST’s quarterly revenue moves. That information asymmetry makes valuation genuinely hard.

Put simply, out-licensing trades away upside, control, and information in exchange for lower risk. Before getting excited about an “IMULDOSA approved” headline, it is worth coldly asking how many royalty dollars that approval actually converts into on Dong-A ST’s income statement.

---

Where does it stand next to Celltrion and Samsung Bioepis?

Place Dong-A ST inside the Korean biosimilar and pharma map and its positioning becomes clear.

Company	Character	Biosimilar scale	Key strength	vs Dong-A ST
Dong-A ST (170900)	Mid-cap traditional pharma + biosimilar niche	Small, out-licensing led	Growth hormone, specific biosimilars	Baseline
Celltrion	Flagship biosimilar name	Large, own global sales	Remsima, Truxima portfolio	Dominant scale and channel
Samsung Bioepis	Samsung-affiliated biosimilar	Large, partner-driven (Organon etc.)	Capital, development speed	Scale and capital edge
Chong Kun Dang	Traditional major pharma	Mid, incremental-drug led	Prescribing sales force, novel drugs	Larger domestic prescription base
Yuhan	Traditional major pharma	Novel-drug licensing (Lazertinib)	Proven R&D and licensing track record	Validated novel-drug licensing

The table shows Dong-A ST’s spot. Celltrion and Samsung Bioepis are heavyweights that push biosimilars through their own global sales or vast capital. Dong-A ST cannot out-scale them, so it competes through out-licensing in specific products (IMULDOSA) and niches like growth hormone.

The most interesting benchmark is Yuhan. Yuhan out-licensed its lung-cancer drug lazertinib to a global big-pharma partner and turned it into a genuine hit — the very success path Dong-A ST’s model aspires to. The nuance: lazertinib is an innovative novel drug, while IMULDOSA is a biosimilar. Novel-drug licensing can compound into blockbuster royalties; biosimilar licensing has its ceiling capped by price competition.

👉 To widen the lens on the global drug value chain, the Cencora stock outlook looks at pharma distribution and GLP-1 volume tailwinds from the US midstream.

---

Can the diabetes and obesity pipeline become a second growth leg?

If IMULDOSA is today’s catalyst, the market’s next fixation is the diabetes and obesity pipeline.

GLP-1 and metabolic drugs are the hottest space in global pharma right now. As the obesity market explodes, any company with a credible candidate earns a valuation premium. If Dong-A ST advances an in-house candidate or a partnership in this area and posts encouraging early data, it could become a second story after IMULDOSA.

But keep a cold head. Early- and mid-stage pipelines fail often. Obesity and diabetes are dominated by giants like Novo Nordisk and Eli Lilly, and a latecomer must prove a differentiated profile — no small task. There is a vast gap between “having a pipeline” and “commercializing that pipeline.”

From an investor’s seat, treat the metabolic pipeline as option value. Success is a big upside, but it is an uncertain future that should not already be priced into today’s share price. Until clinical data arrives, the safe move is to keep those hopes out of the valuation.

---

The risk ledger: balancing the bull case

Dong-A ST’s story is attractive, but the following risks deserve serious weight.

Korean drug-price pressure. Continuous government price control keeps compressing the legacy body’s margin. This is not a passing headwind but a structural feature every Korean pharma carries — the fundamental reason it is hard to build a growth story on the domestic body.

Partner dependence and royalty opacity. IMULDOSA’s results ride on partner selling, and terms are undisclosed. If the partner underperforms, Dong-A ST’s options are limited.

Biosimilar price competition. The Stelara biosimilar market is already crowded with Amgen, Samsung Bioepis, Celltrion and others. Whether IMULDOSA can hold meaningful share and price in that scrum is the open question.

R&D clinical risk. The pipeline, including metabolic candidates, faces binary outcomes — a failed trial can extinguish the hope premium all at once.

FX risk. IMULDOSA royalties and supply revenue are FX-based. A stronger won shrinks won-denominated revenue; a weaker won helps. The larger exports grow, the higher the currency sensitivity.

Momentum volatility. Because the stock reacts sharply to IMULDOSA news, it can fall just as hard on approval delays, partner weakness, or trial failures. When catalyst hopes are pre-baked into the valuation, disappointment cuts deep.

---

Practical playbook for the US investor

A US investor buying Dong-A ST is holding a Korean-listed foreign stock, so the tax and currency mechanics differ from a domestic name.

Scenario 1: sizing it in a healthcare sleeve

Dong-A ST is best used as a niche catalyst bet, not a core biosimilar position. If you want broad biosimilar exposure, larger, more liquid names carry that load; Dong-A ST rides on IMULDOSA momentum plus a re-rating thesis. Given single-stock and foreign-market risk, keep the position small — a satellite weighting you can scale with IMULDOSA data and new licensing news, not a core holding.

Remember it is illiquid on US brokerage rails. Most Americans access it via a broker offering Korean-market execution or through ADR-style depositary access if available; either way, expect wider spreads, FX conversion friction, and thinner information flow than for a US large-cap.

Scenario 2: US tax and currency reality

For a US taxpayer, gains on Dong-A ST are taxed like any capital gain — short-term at ordinary income rates if held a year or less, long-term at preferential rates beyond a year. Foreign stocks do not change that framework, though any Korean tax withheld on dividends may be recoverable via the foreign tax credit. Confirm treatment with a tax professional, since cross-border withholding and reporting (including forms like the FBAR or Form 8938 above certain foreign-asset thresholds) can apply.

The currency layer matters just as much. Your return is priced in Korean won and converted back to dollars, so a stronger dollar erodes the won-based gain even if the shares rise locally. And here is the twist: IMULDOSA’s royalties are themselves FX-based revenue for the company, so the won rate feeds the fundamentals and your translation return at the same time. Two currency exposures stacked on one position.

👉 For the mechanics of taxing cross-border equity gains, see the capital gains tax guide.

Scenario 3: an event-driven approach

Dong-A ST reacts strongly to IMULDOSA approvals and launches, partner results, new licensing deals, and pipeline readouts. A catalyst-calendar approach can fit better than steady dollar-cost averaging.

The edge is in the gap between expectation and reality. On an approval headline the stock rises first, but actual royalties take time to hit the income statement. If results then miss the hope already priced in, it corrects; if the market underrated partner sales until a quarter proves them, it re-rates. Reading that gap is the whole point of event-driven positioning here.

---

Metrics to watch each quarter

If you hold or track Dong-A ST, here is what to read first in the quarterly results and news flow.

Priority one: IMULDOSA overseas revenue and royalty flow. The core signal. Watch how much IMULDOSA-related supply and royalty revenue is growing in Dong-A ST’s quarter, and cross-check it against the partners’ public ustekinumab biosimilar sales. Partner sales are the leading indicator for Dong-A ST’s royalties.

Priority two: Growtropin and legacy prescription defense. Since the body holds the floor, check that growth-hormone and prescription revenue hold up despite price pressure. If the body shrinks faster than expected, the valuation floor wobbles.

Priority three: new out-licensing deals. Any additional out-licensing or pipeline tech-transfer news strengthens the “Dong-A ST is a licensing company” thesis. Watch the deal size and the caliber of the partner.

Priority four: pipeline clinical progress. Trial-stage advances and data readouts in the metabolic and other programs show whether the option value is being realized. Positive data is a re-rating trigger; failure erases the premium.

Taken together, these four let you track two axes at once beyond the headline revenue and profit — is the legacy body holding, and is the overseas catalyst turning into real cash flow?

---

Further reading

• 👉 SD Biosensor (137310) Stock Outlook 2026: normalizing after the COVID windfall
• 👉 Cencora Stock Outlook 2026: drug distribution oligopoly and GLP-1 volume
• 👉 Capital Gains Tax Guide 2026: strategy and practical filing
• 👉 AI Stocks Investment Guide 2026: key names and ETF selection

---

This article is for informational purposes only and is not investment advice. It does not recommend buying or selling any security. Investing in stocks carries the risk of capital loss, and you should make decisions based on your own financial situation and risk tolerance. Any description of a company’s business or outlook reflects the time of writing; always verify the latest disclosures and consult a qualified professional before investing.